These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 18393607)

  • 1. Type I interferons as vaccine adjuvants against infectious diseases and cancer.
    Bracci L; La Sorsa V; Belardelli F; Proietti E
    Expert Rev Vaccines; 2008 Apr; 7(3):373-81. PubMed ID: 18393607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFN-alpha in the generation of dendritic cells for cancer immunotherapy.
    Santini SM; Lapenta C; Santodonato L; D'Agostino G; Belardelli F; Ferrantini M
    Handb Exp Pharmacol; 2009; (188):295-317. PubMed ID: 19031032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulators as adjuvants for vaccines and antimicrobial therapy.
    Nicholls EF; Madera L; Hancock RE
    Ann N Y Acad Sci; 2010 Dec; 1213():46-61. PubMed ID: 20946578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferons as potential adjuvants in prophylactic vaccines.
    Toporovski R; Morrow MP; Weiner DB
    Expert Opin Biol Ther; 2010 Oct; 10(10):1489-500. PubMed ID: 20836750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock proteins as vaccine adjuvants in infections and cancer.
    Segal BH; Wang XY; Dennis CG; Youn R; Repasky EA; Manjili MH; Subjeck JR
    Drug Discov Today; 2006 Jun; 11(11-12):534-40. PubMed ID: 16713905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvants for vaccines, a quest.
    Audibert F
    Int Immunopharmacol; 2003 Aug; 3(8):1187-93. PubMed ID: 12860174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction.
    Mills KH
    Immunol Lett; 2009 Feb; 122(2):108-11. PubMed ID: 19100777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New adjuvants for human vaccines.
    Mbow ML; De Gregorio E; Valiante NM; Rappuoli R
    Curr Opin Immunol; 2010 Jun; 22(3):411-6. PubMed ID: 20466528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translating innate immunity into immunological memory: implications for vaccine development.
    Pulendran B; Ahmed R
    Cell; 2006 Feb; 124(4):849-63. PubMed ID: 16497593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of type I interferon in inducing a protective immune response: perspectives for clinical applications.
    Rizza P; Moretti F; Capone I; Belardelli F
    Cytokine Growth Factor Rev; 2015 Apr; 26(2):195-201. PubMed ID: 25466627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity.
    Prchal M; Pilz A; Simma O; Lingnau K; von Gabain A; Strobl B; Müller M; Decker T
    Vaccine; 2009 Dec; 27 Suppl 6():G17-20. PubMed ID: 20006134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of toll-like receptor therapeutics.
    Parkinson T
    Curr Opin Mol Ther; 2008 Feb; 10(1):21-31. PubMed ID: 18228178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate immunity and new adjuvants.
    Mutwiri G; Gerdts V; Lopez M; Babiuk LA
    Rev Sci Tech; 2007 Apr; 26(1):147-56. PubMed ID: 17633299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use.
    Ferrantini M; Capone I; Belardelli F
    Biochimie; 2007; 89(6-7):884-93. PubMed ID: 17532550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat-shock protein-based vaccines for cancer and infectious disease.
    Binder RJ
    Expert Rev Vaccines; 2008 Apr; 7(3):383-93. PubMed ID: 18393608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvants for cancer vaccines.
    Dubensky TW; Reed SG
    Semin Immunol; 2010 Jun; 22(3):155-61. PubMed ID: 20488726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relevance of cytokines for development of protective immunity and rational design of vaccines.
    Chabalgoity JA; Baz A; Rial A; Grille S
    Cytokine Growth Factor Rev; 2007; 18(1-2):195-207. PubMed ID: 17347024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Updated Review of ISCOMSTM and ISCOMATRIXTM Vaccines.
    Garcia A; Lema D
    Curr Pharm Des; 2016; 22(41):6294-6299. PubMed ID: 27634183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.
    Vollmer J; Krieg AM
    Adv Drug Deliv Rev; 2009 Mar; 61(3):195-204. PubMed ID: 19211030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell immunostimulation by methyl inosine 5'-monophosphate: application to infectious diseases.
    Signorelli KL; Hadden JW
    Int Immunopharmacol; 2003 Aug; 3(8):1177-86. PubMed ID: 12860173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.